Le Lézard
Classified in: Health, Science and technology, Business
Subjects: STOCK/OTHER MARKET NEWS, ANNUAL MEETINGS

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders


TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 27, 2019. The results of the director elections were as follows:

          
  Votes in Favor % Votes in Votes % Votes 
 Name  Favor Withheld Withheld 
 Mr. Luke Beshar5,579,317 85 977,217 15 
 Dr. Robert Kirkman5,614,544 85 941,990 15 
 Dr. Michael Moore5,586,552 85 969,982 15 
 Dr. Thomas Reynolds5,580,252 85 976,282 15 
 Dr. Robert Uger5,615,550 86 940,984 14 
 Dr. Calvin Stiller5,581,832 85 974,702 15 
 Dr. Helen Tayton-Martin5,687,094 87 869,440 13 
          

The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year. In addition, the shareholders approved the special resolutions to continue the Corporation as a British Columbia corporation to be governed by the provisions of the Business Corporations Act and the potential consolidation of the Corporation's issued and outstanding common shares.

About Trillium Therapeutics:

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

For more information visit: www.trilliumtherapeutics.com 

Investor Relations:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com


These press releases may also interest you

at 23:03
Evofem Biosciences, Inc. , a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the pricing of an underwritten...

at 21:56
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the pricing of its initial public offering of 9,000,000 shares of its common...

at 20:40
North Bud Farms Inc. ("NORTHBUD" or the "Company") provides shareholders with the following corporate update: U.S. Operations The Company is pleased to announce that it has signed a definitive agreement to sell all the shares of its U.S....

at 20:01
As COVID-19 regulations ease, U.S.-based health technology company Electronic Caregiver® has developed a digital application to help professional soccer players in Austria resume training and competition as safely as possible....

at 20:00
- More than a third (36%) of regular exercisers are more active now than they were before lockdown - 79% of runners say running is currently helping them feel saner and more in control - 73% of runners want to keep running as much as they are now...

at 20:00
CHAP Accreditation demonstrates that AmeriCare Medical and its subsidiaries: AmeriStaff Nursing Services, Rx iV Infusion Pharmacy and Sun Medical Equipment Company meets the industry's highest nationally recognized standards. The rigorous evaluation...



News published on 2 july 2019 at 07:05 and distributed by: